Pfizer Inc.
Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
Last updated:
Abstract:
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
Status:
Grant
Type:
Utility
Filling date:
20 May 2019
Issue date:
1 Jun 2021